Company news

Beam Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

November 4, 2024

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

November 4, 2024

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

October 28, 2024

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

August 5, 2024

Beam Therapeutics Announces Transition of Chief Financial Officer

July 14, 2024

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

June 25, 2024

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

June 13, 2024

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 29, 2024

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 13, 2024

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

May 6, 2024

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

March 25, 2024

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

February 27, 2024

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

February 26, 2024

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 4, 2024

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

January 7, 2024

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

December 13, 2023

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

November 7, 2023

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

November 7, 2023

Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 30, 2023

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

October 24, 2023

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

October 18, 2023

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

September 6, 2023

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

September 4, 2023

Beam Therapeutics to Participate in Upcoming September Investor Conferences

August 30, 2023

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

August 7, 2023

Beam Therapeutics to Participate in Upcoming May Investor Conferences

May 16, 2023

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

May 10, 2023

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

May 9, 2023

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

March 26, 2023

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

March 20, 2023

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

March 14, 2023

Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference

February 28, 2023

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

February 27, 2023

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

February 6, 2023

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

January 8, 2023

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

December 9, 2022

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

December 1, 2022

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

December 1, 2022

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

November 29, 2022

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

November 13, 2022

Beam Therapeutics to Participate in Upcoming Investor Conferences

November 8, 2022

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

November 6, 2022

Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting

November 2, 2022

Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection

September 18, 2022

Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference

August 31, 2022

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

August 8, 2022

Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

August 1, 2022

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 14 decks. Every deck is listed under its year.